17,261 trials
Plasma Cell Myeloma
Primary: Rate of Minimal Residual Disease (MRD) Negative Response After Autologous Stem Cell Transplantation (ASCT) — 0.652 proportion of participants
Peanut Allergy
Primary: The Proportion of Subjects Mildly Symptomatic or Less at the 12 Month DBPCFC — 4; 4 Participants — p=1.00
Pre Diabetes
Primary: Monitoring Adverse Events — 0; 0 TEAE
22Q11.2 Deletion Syndrome
Primary: Overall Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) — 12; 3 Participants
Papillomavirus Infections · Cervical Intraepithelial Neoplasia · Carcinoma In Situ
Primary: Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR) — 0; 5 Participants
Down Syndrome · Refractive Errors
Primary: Distance Visual Acuity — 0.41; 0.41; 0.40; 0.43 logMAR — p=0.92
Thyroid Eye Disease · Graves Ophthalmopathy · Graves Orbitopathy
Primary: Percentage of Participants Showing a Response in Proptosis Measured Using Hertel Exophthalmometer (≥2 mm Decrease From Baseline) in the Study Eye and Separately in…
Acinar Cell Adenocarcinoma of the Pancreas · Duct Cell Adenocarcinoma of the Pancreas · Stage I Pancreatic Cancer
Primary: Progression Free Survival Rate — 67 percentage of participants
Infiltrating Bladder Urothelial Carcinoma
Primary: Overall Pathological Response Rate — 57.7 % of participants
Hypoxic-Ischemic Encephalopathy · Pain
Primary: Examine Safety Measures in Infants Receiving DMT to Those Receiving Morphine — 1; 1 Number of serious adverse events
Chronic Exertional Compartment Syndrome
Primary: University of Wisconsin Running Injury and Recovery Index Score at Baseline — 10.86; 11.86; 12.14; 9.75 cumulative score on a 9-item scale
Alzheimer's Disease
Primary: Core Study Phase: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at Month 12 — 0.113; 0.134; 0.119; 0.116 score on a scale
Prostate Adenocarcinoma
Primary: 6-Month Radiographic Progression-Free Survival (rPFS6) — 6 Participants — p=0.006
Hypoparathyroidism · Hypocalcemia · Autoimmune Polyendocrine Syndrome Type 1
Primary: Mean Serum Calcium in Children and Young Adults — 2.02; 1.88 mmol/liter — p=0.02
Clostridioides Difficile Infection · Stool Microbiome · Organ Dysfunction Syndrome
Primary: The Superiority of Bezlotoxumab Over Placebo to Reduce the Occurence of an Unfavorable Outcome by Day 40. — 7; 16 Participants — p=0.015